ST. LOUIS, Oct. 11 /PRNewswire/ — Through a set of proprietary
computer models, Express Scripts, Inc. (Nasdaq:
ESRX), is now able to accurately predict up to a year in
advance which patients are most at risk of falling off their
physician-prescribed drug therapy — and to intervene in
customized ways to improve those patients’ adherence.
(Logo:
http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20080827/EXPRESSSCRIPTSLOGO)
Express Scripts announced today the completed testing of its
therapy adherence predictive models. The findings from the tests
demonstrate that the new predictive models are more accurate,
informative, and actionable than any the industry has produced
previously.
The patent-pending models apply to patient behavior in three key
treatment classes: diabetes, high blood pressure, and high
cholesterol. By being able to intervene in a highly targeted way,
Express Scripts can help improve their overall health and reduce
their need for increased medical expenditures in the future.
“The problem of non-adherence isn’t new – it’s easy to
walk through a hospital and identify people who would not be there
if they had simply taken their medications,” said Steven Miller,
M.D., chief medical officer at Express Scripts. “But our new
predictive models allow us to do something that wasn’t possible
before: better identify those patients before they run into
trouble, and tailor practical, patient-centric solutions that
target the specific factors that put them at-risk for
non-adherence.”
Interventions to improve adherence include reminders,
consultations with a pharmacist, lowered co-pays, transition to
home delive
‘/>”/>
SOURCE
